A recent study published in Annals of Internal Medicine reveals that smokers with type 2 diabetes who are treated with Novo Nordisk A/S’ (NYSE:NVO) Ozempic (semaglutide) show fewer tobacco-related medical interactions and interventions aimed at smoking cessation compared to those taking other diabetes medications. In the year following the initiation of Ozempic treatment, patients previously diagnosed with tobacco use disorder were up to 32% less likely to discuss tobacco use with their healthcare providers. This reduction in discussions about tobacco use was observed even when compared to those taking other medications within the same class, known as GLP-1 receptor agonists. Also Read: